GlassScriptPhysician profile
Kori Elkins
NPI 1265691141
$8,916.79
in general payments reported to CMS, 2019-2025
20 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $1,704 · 2021: $278 · 2022: $1,893 · 2023: $3,864 · 2024: $683 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,231 · Food and Beverage: $1,436 · Education: $57.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,231.25 |
| Food and Beverage | $1,436.11 |
| Education | $57.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,161.91 | 2022-2024 | |
| Bausch & Lomb Americas INC. | $2,351.83 | 2022-2025 | Xipere, Stellaris |
| Cardinal Health 108 LLC | $1,575.00 | 2020 | |
| Genentech USA, INC. | $293.20 | 2019-2025 | Vabysmo, Susvimo |
| Regeneron Healthcare Solutions, INC. | $258.09 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $248.30 | 2022-2024 | Syfovre |
| Allergan, INC. | $235.85 | 2019-2021 | |
| Alimera Sciences, INC. | $217.08 | 2019-2023 | Iluvien |
| Eyepoint US, INC. | $148.97 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $95.23 | 2019-2023 | Cequa |
| Astellas Pharma US INC | $89.38 | 2023-2024 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.25 | 2020 | |
| Novartis Pharmaceuticals Corporation | $39.91 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $39.46 | 2019 | |
| Oyster Point Pharma, INC. | $28.18 | 2023 | Tyrvaya |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $21.61 | 2022 | |
| Biogen, INC. | $20.72 | 2023 | |
| Astellas Pharma Global Development | $18.58 | 2024 | Izervay |
| Shire North American Group INC | $15.21 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $14.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kori Elkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.